Article Text

PDF
Characterisation of severe rod–cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene
  1. P Charbel Issa1,
  2. H J Bolz2,
  3. I Ebermann2,
  4. E Domeier1,
  5. F G Holz1,
  6. H P N Scholl1
  1. 1
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  2. 2
    Institute of Human Genetics, University of Cologne, Cologne, Germany
  1. Dr H P N Scholl, Department of Ophthalmology, University of Bonn, Ernst-Abbe-Str. 2, D-53127 Bonn, Germany; hendrik.scholl{at}ukb.uni-bonn.de

Abstract

Aim: To characterise the ocular phenotype of a family segregating the splice site mutation c.2189+1G>T in the tyrosine kinase receptor gene MERTK.

Methods: Five affected children of a consanguineous Moroccan family were investigated by ophthalmic examinations, including fundus photography, autofluorescence (FAF) imaging, optical coherence tomography (OCT), psychophysical and electrophysiological methods.

Results: Affected children were between 5 and 19 years of age, allowing an estimation of disease progression. Electroretinography demonstrated loss of scotopic and photopic function in the first decade of life. Younger siblings showed drusen-like deposits with focal relatively increased FAF in the macular area. With increasing age, a yellowish lesion with relatively increased FAF and subsequent macular atrophy developed. Visual acuity deteriorated with age and ranged between 20/50 in the best eye of the youngest affected and 20/400 in the worst eye of the oldest affected sibling. Spectral-domain OCT revealed debris-like material in the subneurosensory space.

Conclusion: The splice site mutation c.2189+1G>T in MERTK causes rod–cone dystrophy with a distinct macular phenotype. The debris in the subneurosensory space resembles that in the Royal College of Surgeons (RCS) rat being the mertk animal model. Patients might therefore benefit from advances in gene therapy that were previously achieved in the RCS rat.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Funding: Supported by the European Commission Integrated Project “EVI-GENORET” (EU-FP6-LSHG-CT-2005-512036); German Research Foundation (DFG) grant BO 2954/1-1; BONFOR Program, grant O-137.0011 (Faculty of Medicine, University of Bonn); Kroener Foundation (Germering, Germany); Koeln Fortune Program, grant 113/2004 (Faculty of Medicine, University of Cologne); and Forschung contra Blindheit—Initiative Usher-Syndrom eV.

  • The project was in part presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2007, at the Annual Meeting of the German Association for Ophthalmology 2007 and at the Annual Meeting of the German Society of Human Genetics 2007.

  • Ethics approval: Ethics approval was provided by Ethikkommission der Universität Bonn.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.